rajasekharkakarla
☆    

India,
2019-09-20 06:35

Posting: # 20628
Views: 315
 

 Reference replicated designs [Regulatives / Guidelines]

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,885 posts in 4,214 threads, 1,366 registered users;
online 10 (0 registered, 10 guests [including 8 identified bots]).
Forum time (Europe/Vienna): 02:06 CEST

The real purpose of the scientific method is to make sure
nature hasn’t misled you into thinking you know something
you actually don’t know.    Robert M. Pirsig

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5